The prevention of migraine: A critical review with special emphasis on β-adrenoceptor blockers

British Journal of Clinical Pharmacology, Supplement

Volumn 52, Issue 3, 2001, Pages 237-243

  Limmroth, Volker ^a   Michel, Martin C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Metoprolol; Migraine prophylaxis; Propranolol; Trial design

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL; HUMAN; MIGRAINE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; CLINICAL TRIALS; HUMANS; MIGRAINE DISORDERS;

EID: 0035464645     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01459.x     Document Type: Article

References (71)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Ccphalagia 1988; 8(Suppl 7): 1-93.
2. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87: 543-552.
3. Lance JW, Goadsby I'J. Mccliairisiiis and Management of Headache. Buttenvorth-Heinemann, Oxford, 1999: 79-104.
4. Diener HC, Limmroth V. Acute management of migraine: triptans and beyond. Curr Opin Neural 1999; 12: 261-267.
5. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine, 2nd edn. Ccphalalgia. 2000; 20: 765-786.
6. Limmroth V, Kaube H, Diener HC. Management and Prevention of Migraine: a practical guide. In Migraine in Perspective, ed. Mallerkey, G. ADIS Books, Auckland, 1999: 19-33.
7. Diener HC, Mathew NT. Drug-Induced-Headache. In Drug Treatment of Migraine and Oilier Headaches. Monographs in Clincal Keiirvscience, Vol 17, ed. Diener HD. Karger, Basel, 2000: 347-355.
8. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine. A review of its pharmacodyiiamic and pharmacokinetic properties and therapeutic. Drugs 1984; 27: 6-44.
9. Tfelt-Hansen P. Trial design in migraine prophylaxis. In Drug Treatment of Migraine anil Oilier Headaches. Monographs in Clincal Nciiroscicncc, Vol 17, ed. Diener, HD. Karger, Basel, 2000: 244-249.
10. Holdorff B, Sinn M, Roth G. I'ropranolol in der .Migräneprophylaxe. Med Klin 1977; 72: 1115-1118.
11. Stensrud P, Sjaastad O. Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache 1980; 20: 204-207.
12. al-Quassab HK, Findley LJ. Comparison of propranolol LA 80 mg and propranolol 160 mg in migraine prophylaxis, a placebo controlled study. Ccphalalgia 1993; 13: 128-131.
13. Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache 1988; 28: 15-23.
14. Saper JR, Silberstein SD, Lake AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34: 497-502.
15. Kuritzki A, Zoldan Y, Melamed E. Selegeline, a MAO B inhibitor is not effective in the prophylaxis of migraine without aura -an open study. Headaclie 1992; 32:416-417.
16. Anthony M, Lance JW, Somerville B. A comparative trial of prindolol, clonidine and carbamazepine in the interval therapy of migraine. Med J Aust 1972; 1: 1343-1346.
17. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Ccphalalgia 1997; 17: 109-112.
18. The Migraine-Nimodipine European Study Group (MINES). European multicenter trial of nimodipine in the prophylaxis of commen migraine (migraine without aura). Headache 1989; 29: 633-638.
19. Albers GW, Simon LT, Hamik A, Peroutka SJ. Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache 1989; 29: 214-217.
20. Diener HC, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. Ccphalalgia 2001; 21: 66-70.
21. Solomon GD, SteelJG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAAIA 1983; 250: 2500-2502.
22. Markley HG, CheronisJC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984; 34: 973-976.
23. Schrader H, Stovner LJ, Heide G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo controlled crossover study. Er MedJ 2001; 322: 19-26.
24. Holroyd KA, Penzien DB, Rockicki LA, Cordingley GE. Flunarizine versus Propranolol. A meta-analysis of clinical trials. Headache 1992; 32: 256-261.
25. Diener HC. Flunarizine for migraine prophylaxis. In Drug Treatment of Migraine and Other Headaches. Monographs in Clincal Neuroscience, Vol 17, ed. Diener HD. Karger, Basel, 2000: 269-278.
26. Hering R, Kurzitzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Ceplialalgia 1992; 12: 81-84.
27. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994; 44: 647-651.
28. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neural 1995; 52: 281-286.
29. Baldretti A, Cortelli P, Proccaccianti G, Gamberini G, D'Alessandro Baruzzi A. Propanolol and acetylsalicylic acid in migraine prophylaxis. A double blind cross over study. Acta Ncnrol Scand 1983; 67: 181-186.
30. Grotemeyer KH, Scharafmski HW, Schlake HP, Husstedt IW. Acetylsalicylic acid vs metoprolol in migraine prophylaxis -a double blind cross-over study. Headache 1990; 30: 639-641.
31. Diener HC, Härtung E, Chrubasik J. Acetylsalicylic acid in migraine prophylaxis: a double blind study in comparison with metoprolol. Ceplialalgia 1997; 17: 434.
32. Bellavance AJ, Melodie JP. A comparative study of napro.xen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990; 30: 710-715.
33. Kjaersgard Rasmussen MJ, Holt Larsen B, Borg L, Soelberg Sorensen P, Hansen PE. Tolfenamic acid versus propranolol in prophylactic treatment of migraine. Acta Neurol Scand 1994; 89: 446-450.
34. Mylecharane EJ. 5-HT2 receptor antagonists and migraine therapy. J Neurol 1991; 238(Suppl 1): S45-S52.
35. Silberstein SD. Methysergide. Ceplialalgia 1998; 18: 421-435.
36. Rabkin R, Stables DP, Levin NW, Suzman MM. Propanolol and prophylaxis of angina pectoris. Am J Cardiol 1966; 18: 370-380.
37. Anderson KE, Vinge E. β-Adrenoreceptor blockers and calcium antagonists in the prophylaxis of migraine. Drugs 1990; 39: 355-373.
38. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991; 31: 333-340.
39. Tfelt-Hansen P, Shanks RG. β-Adrenoreceptor blocking drugs. In Tlie Headaches, eds Olesen J, Tfelt-Hansen P, Welch KMA. New York, Raven Press, 1993: 263-372.
40. Limmroth V, Mummel P. Migraine Prophylaxis: Beta-blockers. In: Diener HD, ed. Drug Treatment of Migraine and Other Headaches. Manograplis in Clincal Nciiroxicnce, Vol 17. Karger, Basel, 2000: 256-268.
41. CruickshankJM, Pricliard BNC. Bcta-Bkckm in Clinical Pralicc, 2nd edn. Churchill Livingstone, Edinburgh, 1994.
42. Würz R, Reinhardt-Benmalek B, Groteineyer K-H, Foh M. Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura -a randomized double-blind cross-over multicenter study. Cephalalgia 1991; 11(Suppl 11): 152-153.
43. van de Ven LLM, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Ccplialalya 1997; 17: 596-599.
44. Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. Headache 1983; 23: 188-190.
45. Johannsson V, Nilsson LR, Widelius T. Atenolol in migraine prophylaxis: a double-blind cross-over multicenter study. Headache 1987; 27: 372-374.
46. Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc 1984; 84: 343-347.
47. Ryan RE Sr, Ryan RE Jr, Sudilovski A. Nadolol: its use in the prophylactic treatment of migraine. Headache 1983; 23: 26-31.
48. RyaruRE. Comparative study of nadolol and propanolol in prophylactic treatment of migraine. Am Heart J 1984; 108: 1156-1159.
49. Olerud B, Gustavsson CL, Furberg B. Nadolol and propanolol in migraine management. Headache 1986; 26: 490-193.
50. Sudlikovski A, Elkind AH, Ryan RE Sr, Saper JR, Stem MA, Meyer JH. Comparative efficacy of nadolol and propanolol in the management of migraine. Headache 1987; 27: 421-426.
51. Tfelt-Hansen P, Standnes B, Kangasniemi P, Hakkarainen H, Oleson J. Timolol vs. propranolol vs. placebo in common migraine prophylaxis: a double-blind multicenter trial. Ada Neural Scand 1984; 69: 1-8.
52. Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timo\o\.JAMA 1984; 252: 2576-2257.
53. Nanda RN, Johnson RH, GrayJ, Keogh HJ, Melville ID. A double blind trial of acebutolol for migraine prophylaxis. Headache 1978; 18: 20-22.
54. Ekbom K. Alprenolol for migraine prophylaxis. Headache 1975; 15: 129-132.
55. Ekbom K, Zettennan M. Oxprenolol in the treatment of migraine. Acta Ncnwl Scand 1977; 56: 181-184.
56. Sjastaad O, Stenrud P. Clinical trial of a beta-receptor blocking agent (LB46) in migraine prophylaxis. Acta Neural Scand 1972; 48: 124-128.
57. Ekbom K, Lundberg PO. Clinical trial of LB-46 (d, 1-4 (2-hydroxy-3-isopropylaminopropoxy) indol), an adrenergic betareceptor blocking agent in migraine prophylaxis. Headache 1972; 12: 15-17.
58. Castro ME, Harrison PJ, Pazos A, Sharp T. Affinity of ( + / -)-pindolol, ( -)-penbutolol, and (-)-tertatolol for pre- and post-synaptic serotonin 5-HT (1A) receptors in human and rat brain. J Neureichem 2000; 75: 755-762.
59. Voigt MM, Laurie DJ, Seeburg PH, Bach A. Molecular cloning and characterization of a rat brain cDNA encoding a 5-hydroxytryptaminelB receptor. EMBOJ 1991; 10: 4017-4023.
60. ZgombickJM, Bard JA, Kucharewicz SA, Urquhart DA, Weinshank RL, Branchek TA. Molecular cloning and pharmacological characterization of guinea pig 5-HT1B and 5-HT1D receptors. Neuropharmacology 1997; 36: 513-524.
61. Grotemeyer KH, Schlake HP, Husstedt IW. Migräneprophylaxe mit Metoprolol und Flunarizin. - Eine doppelblind-crossover Studie. Nervenarzt 1988; 59: 549-552.
62. Ludin HP. Flunarizine and propanolol in the treatment of migraine. Headache 1989; 29: 218-223.
63. Shimell CJ, Fritz VU, Levien SL. A comparative trial of flunarizine and propranolol in the prevention of migraine. S Afr MedJ 1990; 77: 75-77.
64. LutschgJ, Vassella F. The treatment ofjuvenile migraine using flunarizine or propranolol. Schweiz Med Wochaischr 1990; 120: 1731-1736.
65. Sorensen PS, Larsen DH, Rasmussen MJ, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991; 31: 650-657.
66. Gawel MJ, KreeftJ, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. CanJ Neurol Sci 1992; 19: 340-345.
67. Verspeelt J, Locht P, Amery WK. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Ccplmlalgia 1996; 16: 328-336.
68. Bordini CA, Arruda MA, Ciciarelli MC, Special; JG. Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arq Nairopsiqniatr 1997; 55: 536-541.
69. Kozubski W, Prusinski A. Sodium valproate versus propranolol in the prophylactic treatment of migraine. Neural Nenrochir Pol 1995; 29: 937-947.
70. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997; 54: 1141-1145.
71. During JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990; 264: 1711.